Toward gene therapy in rheumatoid arthritis

References

• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322.
   PubMed Web of Science ®Google Scholar
• Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37(9):1551–1557.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Rheumatoid arthritis - how common is it? [Internet]. 2019 [cited 2019 Nov 26]; Available from: https://cks.nice.org.uk/rheumatoid-arthritis#!backgroundSub:1
   Google Scholar
• Bartok B, Firestein GS. Fibroblast-like synovioctyes: key effector cells in rheumatoid arthritis. Immunol Rev. 2011;233(1):233–255.
   Google Scholar
• Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24(6):733–745.
   PubMed Web of Science ®Google Scholar
• Ledingham J, Snowden N, Ide Z. Diagnosis and early management of inflammatory arthritis. BMJ. 2017;3248(July):j3248.
   Google Scholar
• Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis. BioDrugs. 2009;23(2):111–124.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Salinger DH, Baumgartner SW, et al. A dose–response meta‐analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90(6):828–835.
   PubMed Web of Science ®Google Scholar
• Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77:1405–1412.
   PubMedGoogle Scholar
• van der Heijden JW, Dijkmans BAC, Scheper RJ, et al. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - From bench to bedside. Nat Clin Pract Rheumatol. 2007;3(1):26–34.
   PubMedGoogle Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;16(2):CD00879.
   Google Scholar
• Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502–516.
   PubMed Web of Science ®Google Scholar
• Larsen C, Østergaard J, Larsen SW, et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008;97(11):4622–4654.
   Web of Science ®Google Scholar
• Wallis WJ, Simkin PA, Nelp WB. Protein traffic in human synovial effusions. Arthritis Rheum. 1987;30(1):57–63.
   PubMedGoogle Scholar
• Derendorf H, Möllmann H, Grüner A, et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra‐articular administration. Clin Pharmacol Ther. 1986;39(3):313–317.
   PubMed Web of Science ®Google Scholar
• Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy. Nat Rev Rheumatol. 2014;10(1):11–22.
   PubMed Web of Science ®Google Scholar
• Farahmand L, Darvishi B, Majidzadeh-A K. Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor kB transcription factor decoy oligodeoxynucleotides. Drug Deliv. 2017;24(1):1249–1261.
   PubMed Web of Science ®Google Scholar
• Crooke ST. Molecular mechanisms of action of antisense drugs. Biochimica et Biophysica Acta - Gene Structure and Expression. 1999;1489(1):31–43.
   Google Scholar
• Apparailly F, Jorgensen C. SiRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol. 2013;9(1):56–62.
   PubMed Web of Science ®Google Scholar
• Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A. 1998;95(8):4613–4618.
   PubMed Web of Science ®Google Scholar
• Lechman ER, Keravala A, Nash J, et al. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther. 2003;10(24):2029–2035.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LAB, Van Den Bersselaar L, et al. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin Exp Immunol. 2000;120(2):375–383.
   PubMed Web of Science ®Google Scholar
• Garaulet G, Alfranca A, Torrente M, et al. IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Mol Ther. 2013;21(1):119–130.
   PubMed Web of Science ®Google Scholar
• Vermeij EA, Broeren MGA, Bennink MB, et al. Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis. 2015;74(11):2084–2091.
   PubMed Web of Science ®Google Scholar
• Adriaansen J, Fallaux FJ, de Cortie CJ, et al. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J Gen Virol. 2007;88(6):1717–1721.
   PubMedGoogle Scholar
• Henningsson L, Eneljung T, Jirholt P, et al. Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS One. 2012;7(11):1–8.
   Web of Science ®Google Scholar
• Song P, Yang C, Thomsen JS, et al. Lipidoid-siRNA nanoparticle-mediated IL-1β gene silencing for systemic arthritis therapy in a mouse model. Mol Ther. 2019 Aug 7; 27(8):1424–1435.
   PubMed Web of Science ®Google Scholar
• Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A. 2005;102(24):8698–8703.
   PubMed Web of Science ®Google Scholar
• Wehling P, Reinecke J, Baltzer AWA, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009;20(2):97–101.
   PubMed Web of Science ®Google Scholar
• Howe SJ, Gaspar HB, Thrasher AJ, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients Find the latest version: insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following ge. J Clin Invest. 2008;118(9):3143–3150.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 Find the latest version : insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–3142.
   PubMed Web of Science ®Google Scholar
• Ghivizzani SC, Oligino TJ, Glorioso JC, et al. Direct gene delivery strategies for the treatment of rheumatoid arthritis. Drug Discov Today. 2001;6(5):259–267.
   PubMed Web of Science ®Google Scholar
• Gouze E, Pawliuk R, Pilapil C, et al. In vivo gene delivery to synovium by lentiviral vectors. Mol Ther. 2002;5(4):397–404.
   PubMed Web of Science ®Google Scholar
• Gouze E, Pawliuk R, Gouze JN, et al. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Mol Ther. 2003;7(4):460–466.
   PubMed Web of Science ®Google Scholar
• Roessler BJ, Allen ED, Wilson JM, et al. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest. 1993;92(2):1085–1092.
   PubMed Web of Science ®Google Scholar
• Goossens PH, Schouten GJ, ’T Hart BA, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther. 1999;10(7):1139–1149.
   PubMed Web of Science ®Google Scholar
• Mi Z, Ghivizzani SC, Lechman E, et al. Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res Ther. 2003;5(3):R132.
   PubMed Web of Science ®Google Scholar
• Chirmule N, Propert KJ, Magosin SA, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6(9):1574–1583.
   PubMed Web of Science ®Google Scholar
• Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8(23):1794–1800.
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Embo J. 1991;10(12):3941–3950.
   PubMed Web of Science ®Google Scholar
• Choi VW, McCarty DM, Samulski RJ. Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol. 2006;80(21):10346–10356.
   PubMed Web of Science ®Google Scholar
• Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A. 2007;104(32):13104–13109.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Imagawa T, Boivin GP, et al. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther. 2000;2(2):147–152.
   PubMed Web of Science ®Google Scholar
• Cottard V, Mulleman D, Bouille P, et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther. 2000;7(22):1930–1939.
   PubMed Web of Science ®Google Scholar
• Pan RY, Chen SL, Xiao X, et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. 2000;43(2):289–297.
   PubMedGoogle Scholar
• Zhou Q, Guo R, Wood R, et al. VEGF-C attenuated joint damage in chronic inflammatory arthritis By accelerating local lymphatic drainage. Arthritis Rheum. 2011;63(8):2318–2328.
   PubMedGoogle Scholar
• Khoury M, Courties G, Fabre S, et al. Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum. 2010;62(3):765–770.
   PubMedGoogle Scholar
• Aalbers CJ, Bevaart L, Loiler S, et al. Preclinical potency and biodistribution studies of an AAV 5 vector expressing human interferon-β (ART-I02) for local treatment of patients with rheumatoid arthritis. PLoS One. 2015;10(6):1–17.
   Web of Science ®Google Scholar
• US National Library of Medicine ClinicalTrials.Gov. A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis [Internet]. 2018 [cited 2019 Dec 5]; Available from: https://clinicaltrials.gov/ct2/show/NCT02727764
   Google Scholar
• Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol. 2017;4(1):511–534.
   PubMed Web of Science ®Google Scholar
• Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Educ. 2012;51(34):8529–8533.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Grosse SM, Meng QH, et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials. 2011;32(5):1370–1376.
   PubMed Web of Science ®Google Scholar
• Writer MJ, Marshall B, Pilkington-Miksa MA, et al. Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display. J Drug Target. 2004;12(4):185–193.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Dehaini D, Zhang Y, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat Nanotechnol. 2018;13(12):1182–1190.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease [Internet]. 2018 [cited 2019 Dec 3]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease
   Google Scholar
• Khoury M, Louis-Plence P, Escriou V, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheum. 2006;54(6):1867–1877.
   PubMed Web of Science ®Google Scholar
• Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 2009;17(1):162–168.
   PubMed Web of Science ®Google Scholar
• Khoury M, Escriou V, Courties G, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008;58(8):2356–2367.
   PubMed Web of Science ®Google Scholar
• Courties G, Baron M, Presumey J, et al. Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheum. 2011;63(3):681–690.
   PubMedGoogle Scholar
• Courties G, Seiffart V, Presumey J, et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood. 2010;116(18):3505–3516.
   PubMed Web of Science ®Google Scholar
• Duan W, Li H. Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis. J Nanobiotechnology. 2018;16(1):1–9.
   PubMedGoogle Scholar
• Mease PJ, Wei N, Fudman EJ, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J Rheumatol. 2010;37(4):692–703.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Hobbs K, Chalmers A, et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: A phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis. 2009;68(8):1247–1254.
   PubMed Web of Science ®Google Scholar
• Fabre S, Apparailly F. Gene therapy for rheumatoid arthritis: current status and future prospects. BioDrugs. 2011;26(6):381–391.
   Google Scholar
• Présumey J, Salzano G, Courties G, et al. PLGA microspheres encapsulating siRNA anti-TNFalpha: efficient RNAi-mediated treatment of arthritic joints. Eur J Pharm Biopharm. 2012;82(3):457–464.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine ClinicalTrials.Gov. ISIS 104838, an inhibitor of tumor necrosis factor, for active rheumatoid arthritis [ClinicalTrials.gov identifier: NCT00048321]. 2002; Available from: https://clinicaltrials.gov/ct2/show/NCT00048321
   Google Scholar
• Sewell KL, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther. 2002;303(3):1334–1343.
   PubMed Web of Science ®Google Scholar
• Crooke ST. editor. Antisense drug technology: principles, strategies, and applications, Edited by, Crooke ST. 2nd. Boca Raton: CRC Press; 2008. p. 673–674
   Google Scholar
• Raoof AA, Chiu P, Ramtoola Z, et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. [Internet] J Pharm Sci. 2004;93(6):1431–1439. .
   PubMed Web of Science ®Google Scholar
• Kay JD, Gouze E, Oligino TJ, et al. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med. 2009;11(7):605–614.
   PubMed Web of Science ®Google Scholar
• Smeets RL, van de Loo FAJ, Arntz OJ, et al. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 2003;10(12):1004–1011.
   PubMed Web of Science ®Google Scholar
• Takanashi M, Oikawa K, Sudo K, et al. Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther. 2009;16(8):982–989.
   PubMed Web of Science ®Google Scholar
• Xu G, Nie H, Li N, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005;115(4):1060–1067.
   PubMed Web of Science ®Google Scholar
• Woods JM, Katschke KJ, Tokuhira M, et al. Reduction of inflammatory cytokines and prostaglandin E 2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol. 2000;165(5):2755–2763.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LAB, Chabaud M, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 2000;105(12):1697–1710.
   PubMed Web of Science ®Google Scholar
• Woods AM, Thompson SJ, Wooley PH, et al. Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: A model for the therapy of rheumatoid arthritis. Arthritis Rheum. 2005;52(12):3761–3771.
   PubMedGoogle Scholar
• van Holten J, Reedquist K, Sattonet-Roche P, et al. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2004;6(3):R239–49.
   PubMed Web of Science ®Google Scholar
• Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9(1):24–33.
   PubMed Web of Science ®Google Scholar
• Ali M, Khalid M. Surgical synovectomy for rheumatoid arthritis: a comprehensive literature review. Int Surg J. 2016;3(4):1705–1710.
   Google Scholar
• Nagata S, Golstein P. The fas death factor. Science. 1995;267(5203):1449–1456.
   PubMed Web of Science ®Google Scholar
• Yao Q, Glorioso JC, Evans CH, et al. Adenoviral mediated delivery of FAS ligand to arthritic joints causes extensive apoptosis in the synovial lining. J Gene Med. 2000;2(3):210–219.
   PubMed Web of Science ®Google Scholar
• Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest. 1995;96(3):1631–1638.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao G, Clayburne G, et al. Elimination of rheumatoid synovium in situ using a Fas ligand “gene scalpel.”. Arthritis Res Ther. 2005;7(6):R1235.
   PubMed Web of Science ®Google Scholar
• Yao Q, Wang S, Glorioso JC, et al. Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol Ther. 2001;3(6):901–910.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22(56REV. ISS. 8):9030–9040.
   PubMedGoogle Scholar
• Tak PP, Smeets TJM, Boyle DL, et al. P53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum. 1999;42(5):948–953.
   PubMedGoogle Scholar
• Inazuka M, Tahira T, Horiuchi T, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford). 2000;39(3):262–266.
   PubMed Web of Science ®Google Scholar
• Konisti S, Kiriakidis S, Paleolog EM. Hypoxia-a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(3):153–162.
   PubMed Web of Science ®Google Scholar
• Miotla J, Maciewicz R, Kendrew J, et al. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Investig. 2000;80(8):1195–1205.
   PubMed Web of Science ®Google Scholar
• Afuwafe AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther. 2003;10(23):1950–1960.
   PubMed Web of Science ®Google Scholar
• Kim JM, Ho SH, Park EJ, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. 2002;46(3):793–801.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wood R, Schwarz EM, et al. Near-infrared lymphatic imaging demonstrates the dynamics of lymph flow and lymphangiogenesis during the acute versus chronic phases of arthritis in mice. Arthritis Rheum. 2010;62(7):1881–1889.
   PubMedGoogle Scholar
• Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen‐induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 1999;42(12):2532–2542.
   PubMed Web of Science ®Google Scholar
• Wardwell PR, Forstner MB, Bader RA. Investigation of the cytokine response to NF-ΚB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis in vitro models. Arthritis Res Ther. 2015;17(310). Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0824-x#rightslink
   PubMedGoogle Scholar
• Yamamoto A, Fukuda A, Seto H, et al. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum. 2003;48(9):2682–2692.
   PubMedGoogle Scholar
• Moran-Moguel MC, Del RSP, Mayorquin-Galvan EE, et al. Rheumatoid arthritis and miRNAs: A critical review through a functional view. J Immunol Res. 2018;2018:2474529. Available from: https://www.hindawi.com/journals/jir/2018/2474529/
   PubMed Web of Science ®Google Scholar
• Vicente R, Noël D, Pers YM, et al. Deregulation and therapeutic potential of microRNAs in arthritic diseases. Nat Rev Rheumatol. 2016;12(4):211–220.
   PubMed Web of Science ®Google Scholar
• Long L, Yu P, Liu Y, et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol. 2013;2013:296139. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24151514
   PubMedGoogle Scholar
• van de Loo FAJ, Ask DH, Smeets RL, et al. An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther. 2004;11(7):581–590.
   PubMed Web of Science ®Google Scholar
• Broeren MGA, de Vries M, Bennink MB, et al. Disease-regulated gene therapy with anti-inflammatory interleukin-10 under the control of the CXCL10 promoter for the treatment of rheumatoid arthritis. Hum Gene Ther. 2016;27(3):244–254.
   PubMed Web of Science ®Google Scholar
• Adriaansen J, Khoury M, De Cortie CJ, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis. 2007;66(9):1143–1150.
   PubMed Web of Science ®Google Scholar
• Khoury M, Adriaansen J, Vervoordeldonk MJBM, et al. Inflammation‐inducible anti‐TNF gene expression mediated by intra‐articular injection of serotype 5 adeno‐associated virus reduces arthritis. J Gene Med. 2007;9(7):596–604.
   PubMed Web of Science ®Google Scholar
• Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000;7(6):493–498.
   PubMed Web of Science ®Google Scholar
• Mohamed H, Chernajovsky Y, Gould D. Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application. Sci Rep. 2016;6(1):1–13.
   PubMedGoogle Scholar
• Yang C, Gao S, Kjems J. Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. J Mater Chem B. 2014;2(48):8608–8615.
   PubMed Web of Science ®Google Scholar
• Qin J, Liang J, He Y, et al. Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis. Nano Res. 2018;11(11):6086–6101.
   Web of Science ®Google Scholar
• Li R, He Y, Zhu Y, et al. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 2019;19(1):124–134.
   PubMed Web of Science ®Google Scholar
• Yang YH, Rajaiah R, Ruoslahti E, et al. Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis. Proc Natl Acad Sci U S A. 2011;108(31):12857–12862.
   PubMed Web of Science ®Google Scholar
• Wythe SE, DiCara D, Taher TEI, et al. Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide. Ann Rheum Dis. 2013;72(1):129–135.
   PubMed Web of Science ®Google Scholar
• Mi Z, Lu X, Mai JC, et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther. 2003;8(2):295–305.
   PubMed Web of Science ®Google Scholar
• Gouze E, Gouze JN, Palmer GD, et al. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther. 2007;15(6):1114–1120.
   PubMed Web of Science ®Google Scholar